March 09, 2026-
Solid Biosciences announced that it has entered into a securities purchase agreement with a group of institutional investors to raise approximately $240 million through a private placement, strengthening the company’s financial position as it advances its pipeline of AAV-based gene therapies for rare neuromuscular and cardiac diseases.
Under the agreement, the company will sell 14,973,257 shares of common stock at $5.61 per share, along with pre-funded warrants to purchase up to 27,807,482 additional shares at $5.609 per warrant. Each warrant carries an exercise price of $0.001 per share and can be exercised immediately until fully utilized. The transaction is expected to close on or around March 9, 2026, subject to customary closing conditions.
The financing was supported by both new and existing institutional investors, including Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, Vestal Point Capital, Janus Henderson Investors, and Deep Track Capital.
Solid Biosciences plans to use the net proceeds to advance its pipeline of genetic medicines, support business development initiatives, and fund working capital and general corporate activities. The company is currently developing several AAV gene therapy candidates targeting rare diseases, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), and SGT-601 for TNNT2-mediated dilated cardiomyopathy.
Beyond its therapeutic pipeline, Solid Biosciences is also developing novel genetic regulator libraries and delivery technologies aimed at improving the effectiveness and precision of gene therapies across multiple disease areas.
Leerink Partners and Citigroup served as joint lead placement agents for the financing, while Cantor acted as co-lead placement agent. Truist and H.C. Wainwright & Co. participated as co-placement agents.
